May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Highly Permeable Prodrug of Celecoxib and Its Encapsulation in PLGA Nanoparticles for Enhanced Transscleral Drug Delivery to the Retina
Author Affiliations & Notes
  • N. P. Cheruvu
    Univ of Nebraska Medical Ctr, Omaha, Nebraska
    Pharmaceutical Sciences,
  • P. K. Malik
    Univ of Nebraska Medical Ctr, Omaha, Nebraska
    Pharmaceutical Sciences,
  • S. Sundaram
    Univ of Nebraska Medical Ctr, Omaha, Nebraska
    Pharmaceutical Sciences,
  • U. B. Kompella
    Univ of Nebraska Medical Ctr, Omaha, Nebraska
    Pharmaceutical Sciences,
    Ophthalmology,
  • Footnotes
    Commercial Relationships N.P. Cheruvu, Univ of Nebraska Medical Ctr, P; P.K. Malik, Univ of Nebraska Medical Ctr, P; S. Sundaram, None; U.B. Kompella, Univ of Nebraska Medical Ctr, P.
  • Footnotes
    Support NIH grants DK064172 and EY013842
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3195. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. P. Cheruvu, P. K. Malik, S. Sundaram, U. B. Kompella; Highly Permeable Prodrug of Celecoxib and Its Encapsulation in PLGA Nanoparticles for Enhanced Transscleral Drug Delivery to the Retina. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3195. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To determine the sclera and sclera-choroid-RPE permeability and in vivo transscleral delivery of a novel prodrug of celecoxib and to further compare the transscleral retinal drug delivery from periocular PLGA nanoparticles containing celecoxib or its prodrug.

Methods:: In vitro transport studies for celecoxib and its prodrug were performed for 6 hours using freshly excised bovine sclera and sclera-choroid-RPE. The cytotoxicity of the prodrug was assessed in ARPE-19 cells. Sprague Dawley rats were used to study the in vivo distribution of celecoxib and prodrug following periocular injection of plain drug or prodrug. Further, drug delivery from periocular PLGA nanoparticles containing drug or prodrug was also assessed. At 15 min following plain formulation and 7 days after nanopartilce dosing, the animals were euthanized, the eyes were enucleated and frozen, and the concentrations of celecoxib and the prodrug in the isolated retina were estimated using a HPLC assay.

Results:: Prodrug did not exert any cytotoxicity in ARPE-19 cells. The prodrug exhibited 4-fold higher scleral permeability and 40-fold higher sclera-choroid-RPE permeability compared to celecoxib. Periocular injection of the plain prodrug resulted in 7-fold higher effective (drug plus prodrug) retinal drug delivery compared to dosing with plain drug. Prodrug encapsulated PLGA nanoparticles resulted in 2-fold higher levels of celecoxib in the retina compared to celecoxib PLGA nanoparticles at the end of 1 week.

Conclusions:: Chemical modifications to the drug are useful in enhancing transscleral drug delivery in vitro and in vivo. Encapsulation of permeable prodrug, in particulate systems enhances transscleral retinal drug delivery, while sustaining the same.

Keywords: drug toxicity/drug effects • diabetic retinopathy • retinal pigment epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×